Chronic HIV disease and activation of the coagulation system

Area of Science:

• Hematology
• Infectious Diseases
• Immunology

Background:

• Effective antiretroviral therapy has shifted HIV disease morbidity from AIDS-defining events to non-AIDS complications.
• Persistent coagulation abnormalities are increasingly recognized as a risk factor for thrombotic events in individuals with HIV.
• Understanding these hemostatic changes is crucial for managing long-term HIV care.

Purpose of the Study:

• To investigate the mechanisms underlying altered coagulation in chronic HIV disease.
• To identify the contribution of HIV, antiretroviral therapy, and lifestyle factors to a pro-coagulant state.
• To explore the clinical consequences of HIV-associated coagulation changes.

Main Methods:

• Review of existing literature on HIV, coagulation, and thrombotic disease.
• Analysis of factors contributing to a pro-coagulant state, including tissue factor activity and anticoagulant response.
• Examination of the role of immune activation, vascular disease, and hepatic function in HIV-related hemostatic alterations.

Main Results:

• HIV disease, treatment, and lifestyle factors promote a pro-coagulant state.
• This state involves increased tissue factor activity and a diminished anticoagulant response.
• Systemic immune activation and vascular disease are key contributors to altered coagulation.

Conclusions:

• Coagulation alterations in HIV are linked to persistent immune activation and vascular disease.
• The clinical impact and potential mitigation strategies for HIV-related coagulation changes require further investigation.
• Research continues to focus on the unique aspects of HIV-associated hemostatic changes and therapeutic interventions.